-
Group heroes compete to increase R&D investment, domestic innovative drugs will show a blowout trend
Time of Update: 2021-12-29
In recent years, pharmaceutical companies have placed more emphasis on innovative drugs, and with the continuous increase in R&D investment, the approval of domestically-made innovative drugs has also shown a blowout trend .
-
Guotan medicines have started to apply online!
Time of Update: 2021-12-29
On December 3, the results of the 2021 national drug negotiations were finally "officially announced.
Newly added medicines in the medical insurance catalogueNew medical insurance negotiation drugs
-
Under the implementation of the new version of the Pharmacopoeia, microbiological testing equipment in the subdivision of pharmaceutical equipment is promising
Time of Update: 2021-12-29
The 2021 semi-annual report of Tailin Biology shows that the company's main business is the research and development, manufacturing and sales of pharmaceutical equipment such as microbial detection and control technology system products and organic matter analysis instruments .
-
Talents from multinational pharmaceutical companies are accelerating their transfer to China, and local pharmaceutical companies have both opportunities and challenges
Time of Update: 2021-12-29
Recently, AstraZeneca officially announced to employees that Yin Min, head of AstraZeneca’s China Oncology Division, and Wang Dong, head of retail division, have decided to leave AstraZeneca to seek e
-
In November, the amount of holdings in the pharmaceutical and biological industry exceeded 100 million yuan
Time of Update: 2021-12-29
Looking back at the increase in shares held by the directors, supervisors and senior executives of listed companies on the Shanghai and Shenzhen stock exchanges in November and their affiliates, the cumulative increase in holdings during the month was approximately 421 million yuan, involving 91 companies .
-
Two more senior executives of multinational pharmaceutical companies may switch to local companies
Time of Update: 2021-12-29
Eid, an expert in the medical field, officially announced that he had joined Hengrui Pharmaceuticals as executive vice president, chief medical officer and head of global drug development.
-
The number of pharmaceutical companies listed on the Sci-tech Innovation Board hit a new high, reaching 34 in 2021
Time of Update: 2021-12-28
In these three years, the number of pharmaceutical and biological companies listed on the Sci-tech Innovation Board has continued to hit new highs, from 14 listed in 2019 to 28 in 2020.
-
With the continuous emergence of innovative achievements, the license outs of domestic pharmaceutical companies are becoming more frequent
Time of Update: 2021-12-28
It is understood that in the near future, Shanghai Pharmaceuticals has also announced an exclusive license agreement with HUYABIO, authorizing it to obtain the rights to manufacture, develop and commercialize SPH6162 outside of China .
-
700 million cardiovascular injections!
Time of Update: 2021-12-28
According to data from Meinenet, in 2020, the sales of nicorandil for terminal injection in China's public medical institutions exceeded the 700 million yuan mark, an increase of more than 50% year-on-year in the first half of this year, and the only manufacturer was Beijing Sihuan Kebao Pharmaceutical .
-
20 gynecological Chinese patent medicine into pharmacies sweet and pastry!
Time of Update: 2021-12-28
2021E: TOP20 gynecological Chinese patent medicine brands in physical pharmacies in key citiesSource: Mi Nei. com's terminal competition pattern of physical pharmacies in key citiesAmong the TOP20 brands, Dingkundan of Shanxi Guangyuyuan National Medicines, Jieryin Lotion of Sichuan Enwei Pharmaceutical, and Baofukang Suppository of Hainan Bikai Pharmaceutical are ranked in the top three; in terms of the number of brands, Zhuzhou Qianjin Pharmaceutical There are 4 at most, and Jiawei Xiaoyao pills have been added compared to last year .
-
What are the reasons behind the recent surge in prices of Chinese medicine products?
Time of Update: 2021-12-28
On December 13, China Resources Sanjiu replied to investors on the interactive platform that due to the continuous increase in overall costs in recent years and other reasons, the ex-factory price of the company's Angong Niuhuang Wan has increased this year .
-
Since December, many Chinese and foreign pharmaceutical companies have announced that they will "hand in hand" to develop new drugs!
Time of Update: 2021-12-28
According to the agreement, Deqi Pharmaceuticals will be responsible for the development of the clinical trial and provide financial support, and will have the global commercialization and development rights of ATG-017; and Bristol-Myers Squibb will provide dose ramping and dose expansion of the combination therapy Odivo® needed in research .
-
The procurement of "three high" drugs in 14 provinces will start with 38 varieties...
Time of Update: 2021-12-28
On December 13, the Office of the Procurement Leading Group of the Alliance of Fourteen Provinces (autonomous Regions, Municipalities, and Corps) led by the Henan Provincial Medical Insurance Bureau issued the "Henan, Jin, Mongolia, Jiangxi, Guangdong, Guiyu, Gui Yu, Yunnan, Shaanxi and Qing Ningxin Corps Fourteen Provinces (districts, cities, corps) Corps) Pharmaceutical Joint Purchase Documents (Draft for Solicitation of Comments)", soliciting opinions from the public until December 15 .
-
Regal and Eli Lilly join hands in the industry: License-out projects for Chinese pharmaceutical companies will become increasingly popular
Time of Update: 2021-12-28
According to the terms of the agreement, Jiyu Medicine will exclusively license the development, production and commercialization rights of the KRAS inhibitor JMKX1899 with independent intellectual property rights outside the Greater China Region to Huya, and the relevant rights and interests of JMKX1899 in the Greater China Region will remain with Jimin Trust.
-
Simcere Pharmaceuticals declares new drug for Alzheimer's disease
Time of Update: 2021-12-28
This protein is not only related to the β-amyloid peptide polymerized into plaques that is widely observed in AD patients, but also to Alzheimer's disease (AD ) Other pathological factors have adverse effects, including tau pathological manifestations, neuroinflammation and impaired synaptic function .
-
The opportunity to "get on the bus" in the pharmaceutical sector has arrived!
Time of Update: 2021-12-28
Since November, the pharmaceutical sector has rebounded, with Pharmaceutical Biology (Shenwan) rising by more than 3%, and public offerings have also actively deployed the pharmaceutical track . Acc
-
What can pharmaceutical companies do to help Chinese medicine "go global"?
Time of Update: 2021-12-28
In this context, pharmaceutical companies can continue to promote the development of the Chinese medicine industry in a high-quality direction through technological innovation, the development of modern Chinese medicine scientific research and industrial production technology .
-
Pharmacy services in pharmacies begin to grade
Time of Update: 2021-12-28
2. Health protection function: patient-centered, drug treatment management is the core content, and professional pharmacy services are provided .
In addition, the document divides the professional services provided by social pharmacies into three levels: primary pharmacy, basic pharmacy, and advanced pharmacy .
-
CD22 ADC: Pfizer's "Inizumab ozogamicin" will be approved soon
Time of Update: 2021-12-28
The approval is based on the results of the Phase 3 INO-VATEALL trial, a randomized, open-label, international, multi-center study that included 326 adult patients with relapsed or refractory B-cell ALL and compared the efficacy of BESPONSA with standard chemotherapy And security .
-
The continuous evolution of the old and new in the pharmaceutical industry will play the two strong voices of the development of pharmaceutical equipment
Time of Update: 2021-12-28
In terms of policies, a series of medical reform policies in recent years, including consistency ratings, centralized drug procurement, medical insurance control fees, and speeding up the review and review of new drugs, have continued to force the transformation and upgrading of the pharmaceutical industry, and the country has ushered in a major trend of innovation.
